University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Adding Malabsorption for Failed Gastric Bypass

Completed

Conditions: Clinically Severe Obesity
Obesity Recidivism
Inadequate Initial Weight Loss
Poor Weight Loss
Persistent Obesity
Refractory Obesity
Intractable Obesity

First Posted Date: 2009-12-29

Last Posted Date: 2009-12-29

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 19

Registration Number: NCT01040481

Locations: 🇺🇸
UCSF Fresno Center for Medical Education and Research, Fresno, California, United States

Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

Phase 2

Completed

Conditions: Autistic Disorder

Interventions: Dietary Supplement: Placebo
Drug: Methyl B12

First Posted Date: 2009-12-25

Last Posted Date: 2017-02-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 57

Registration Number: NCT01039792

Locations: 🇺🇸
UCSF, San Francisco, California, United States

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Leukemia
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Monosomy 7
Bone Marrow Clonal Malformations
Biphenotypic Leukemia
Juvenile Myelomonocytic Leukemia
Acute Lymphoblastic Leukemia
Pre-leukemic Syndromes
Myelodysplastic Syndromes

Interventions: Other: Withdrawal of immunosuppression and donor lymphocyte infusion

First Posted Date: 2009-12-21

Last Posted Date: 2016-06-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 43

Registration Number: NCT01036009

Locations: 🇺🇸
University of California, San Francisco, California, United States
🇺🇸
All Children's Hospital, St. Petersburg, Florida, United States

Ketoconazole and Dexamethasone in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ketoconazole
Drug: Hydrocortisone
Drug: Dexamethasone

First Posted Date: 2009-12-21

Last Posted Date: 2020-06-29

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 32

Registration Number: NCT01036594

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Pilot Study on the Tolerability of Dietary Dried Plum

Not Applicable

Completed

Conditions: Healthy
Elderly

Interventions: Dietary Supplement: dried plum powder

First Posted Date: 2009-12-18

Last Posted Date: 2020-03-02

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT01035372

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Phase 1

Withdrawn

Conditions: Tumors

First Posted Date: 2009-12-14

Last Posted Date: 2013-05-13

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01031212

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

HIV Persistence and Viral Reservoirs

Phase 4

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: Raltegravir, tenofovir/emtricitabine

First Posted Date: 2009-12-03

Last Posted Date: 2020-07-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 16

Registration Number: NCT01025427

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Practicing Restorative Yoga or Stretching for the Metabolic Syndrome

Not Applicable

Completed

Conditions: Metabolic Syndrome

Interventions: Behavioral: Restorative yoga
Behavioral: Stretching

First Posted Date: 2009-12-03

Last Posted Date: 2014-06-26

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 180

Registration Number: NCT01024816

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
Unversity of California, San Francisco, San Francisco, California, United States

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine, Bosutinib

First Posted Date: 2009-12-03

Last Posted Date: 2014-05-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 3

Registration Number: NCT01025570

Locations: 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Palliation of Thirst in ICU Patients

Early Phase 1

Completed

Conditions: Thirst

Interventions: Behavioral: combined therapy treatment

First Posted Date: 2009-11-18

Last Posted Date: 2013-03-08

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 353

Registration Number: NCT01015755

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy